股票代码：300363 股票简称：博腾股份 公告编号：2026-004 号 重庆博腾制药科技股份有限公司 关于与关联方形成共同投资暨关联交易的公告 公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、交易概述 重庆博腾制药科技股份有限公司（以下简称"公司"）全资子公司重庆博腾 生物医学研究院有限公司（以下简称"博腾生物研究院"）持有苏州博腾生物制 药有限公司（以下简称"苏州博腾"）42.7818%股权，苏州博航生物技术中心（有 限合伙）（以下简称"苏州博航"）持有苏州博腾 0.0888%股权。苏州博航的执行 事务合伙人苏州博晖生物科技有限责任公司（以下简称"苏州博晖"）拟将其持 有的苏州博航 47.3683%份额（对应 44.9999 万元出资额）转让给陈晖先生。本次 转让完成后，陈晖先生将作为苏州博航的有限合伙人，间接投资苏州博腾。 陈晖先生系公司副总经理、首席财务官，根据《深圳证券交易所创业板股票 上市规则》等相关规定，陈晖先生系公司关联自然人，本次陈晖先生单方面受让 苏州博航财产份额后，将与公司形成关联方共同投资关系。 公司于 2026 年 2 月 2 日 ...

住所：应城市长江埠发展大道 1 号 股票代码：300363 股票简称：博腾股份 公告编号：2026-005 号 重庆博腾制药科技股份有限公司 关于全资子公司完成工商变更登记的公告 公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 为统一"博腾"对外的品牌形象，同时加强重庆博腾制药科技股份有限公司 （以下简称"公司"）对下属子公司的集中管理，更好地推进业务发展，公司决 定将全资子公司湖北宇阳药业有限公司更名为湖北博腾药业有限公司。 近日，该全资子公司已完成工商变更登记手续，并收到应城市市场监督管理 局核发的《营业执照》，具体信息如下： 统一社会信用代码：91420981084900531J 名称：湖北博腾药业有限公司 类型：有限责任公司（自然人投资或控股的法人独资） 法定代表人：白银春 注册资本：3,120 万元整 成立日期：2013 年 11 月 29 日 经营范围：许可项目：药品生产，药品委托生产，药品进出口，危险化学品 生产。（依法须经批准的项目，经相关部门批准后方可开展经营活动，具体经营 项目以相关部门批准文件或许可证件为准） 一般项目：基础化学原料制造（不 ...

股票代码：300363 股票简称：博腾股份 公告编号：2026-003 号 重庆博腾制药科技股份有限公司 第六届董事会第六次临时会议决议公告 公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 会议召开符合《公司法》及《公司章程》的规定，所作决议合法有效。 一、会议审议情况 会议在保证所有董事充分发表意见的前提下，以投票表决方式通过以下议案： （一）审议通过《关于与关联方形成共同投资暨关联交易的议案》。 同意苏州博航生物技术中心（有限合伙）（以下简称"苏州博航"）的执行 事务合伙人苏州博晖生物科技有限责任公司将其持有的苏州博航 47.3683%份额 （对应 44.9999 万元出资额）转让给公司副总经理、首席财务官陈晖先生。本次 转让完成后，陈晖先生将作为苏州博航的有限合伙人，间接投资公司二级控股子 公司苏州博腾生物制药有限公司，与公司形成关联方共同投资关系。具体内容请 见公司同日于巨潮资讯网（www.cninfo.com.cn）发布的《关于与关联方形成共 同投资暨关联交易的公告》（公告编号：2026-004 号）。 本议案已经公司第六届董事会独立董事专门委员会第二 ...

Core Viewpoint - The company aims to restore revenue growth and achieve profitability by 2025, focusing on business expansion and improving management systems [2] Financial Performance - The company forecasts a revenue of 3.35 billion to 3.5 billion yuan for 2025, representing a year-on-year growth of 11% to 16% [2] - The projected net profit attributable to shareholders is between 80 million to 105 million yuan, indicating a turnaround to profitability [2] Operational Factors - Project delivery is influenced by customer order targets and production scheduling, which may lead to quarterly fluctuations [2] - Net profit is also subject to variations due to product mix and expenses, potentially causing quarterly volatility [2]

Core Viewpoint - The report highlights the significant growth and development of China's Contract Research Organization (CRO) industry, driven by a comprehensive policy framework and regulatory reforms that enhance innovation and operational efficiency in the pharmaceutical sector [1][3][9]. Group 1: Industry Overview - The main listed companies in China's CRO industry include WuXi AppTec (603259.SH), Kanglong Chemical (300759.SZ), Tigermed (300347.SZ), Kelaiying (002821.SZ), Zhaoyan New Drug (603127.SH), Jiuzhou Pharmaceutical (603456.SH), Haoyuan Pharmaceutical (688131.SH), Boteng Co., Ltd. (300363.SZ), Chengdu XianDao (688222.SH), and Yaoshi Technology (300725.SZ) [1]. - The CRO industry is recognized as a strategic emerging industry that supports pharmaceutical innovation, transitioning China from a major pharmaceutical market to a strong one [1]. Group 2: Policy Framework - The policy framework for the CRO industry is centered around the National Medical Products Administration (NMPA) and includes collaboration with other regulatory bodies such as the National Health Commission (NHC) and the Drug Administration (CDR) [3]. - Key regulatory measures include the Marketing Authorization Holder (MAH) system, implicit licensing for clinical trials, Good Laboratory Practice (GLP) and Good Clinical Practice (GCP) certifications, and priority review and approval processes [3]. Group 3: Industry Support Policies - National policies provide financial support through initiatives like the "Major New Drug Creation" program, tax reductions for high-tech enterprises, and increased deductions for R&D expenses, which lower operational costs for the industry [6]. - Local governments implement differentiated policies that align with regional industrial characteristics, including subsidies for innovative drug development and funding for CRO platform construction [6]. Group 4: Drug Review Reforms - Recent reforms in drug review processes have significantly improved approval efficiency, reducing the average clinical trial review time from 420 days to 30 days in pilot areas, and addressing a backlog of 22,000 cases [9][12]. - The definition of new drugs has shifted from "China New" to "Global New," aligning with international standards and enhancing the quality of innovation [12]. Group 5: Future Trends - The future of the CRO industry in China is expected to be driven by a robust policy framework, with trends including deeper collaboration in service models, increased application of AI and digital platforms, and a focus on specialized market segments [13]. - The competitive landscape is anticipated to evolve with the rise of domestic leaders and accelerated internationalization, benefiting from improved mechanisms for mutual recognition of clinical trial data [13].

Group 1: Market Overview - The three major indices closed higher, with the overall market sentiment improving as previous hot themes rebounded [9] - The Shanghai Composite Index rose by 0.14% to close at 4122.58, while the ChiNext Index increased by 1.01% to 3328.65 [9][10] - The trading volume across the market reached approximately 27,164.05 billion, an increase of 926.58 billion from the previous trading day [10] Group 2: Economic Insights - The first batch of 936 billion yuan in ultra-long-term special government bonds has been allocated to support equipment renewal across various sectors, expected to drive total investment exceeding 460 billion yuan [18] - The People's Bank of China conducted a 2102 billion yuan reverse repurchase operation with a fixed rate of 1.40%, resulting in a net injection of 309 billion yuan [20] Group 3: Industry Dynamics - The International Energy Agency has raised its forecast for global oil demand growth in 2026 to an average increase of 930,000 barrels per day, up from a previous estimate of 860,000 barrels [29] - The China Chain Store and Franchise Association reported that 59.8% of surveyed chain restaurant enterprises expect an increase in the number of stores in 2025, primarily driven by large enterprises [31] - The output of negative electrode materials in China is projected to reach 2.922 million tons in 2025, marking a year-on-year growth of 38.1% [35] Group 4: Company Updates - Daikin Heavy Industries (002487.SZ) anticipates a net profit of 1.05 to 1.2 billion yuan for 2025, representing a year-on-year increase of 121.58% to 153.23% [45] - Boteng Co., Ltd. (300363.SZ) expects its revenue for 2025 to be between 3.35 to 3.5 billion yuan, with a growth rate of 11% to 16% [47] - Founder Technology (600601.SH) forecasts a net profit of 430 to 510 million yuan for 2025, indicating a growth of 67.06% to 98.14% year-on-year [48]

Group 1: Company Fundraising and Investment - Company plans to use 500 million yuan of raised funds to increase capital in its wholly-owned subsidiaries for the implementation of a DRAM investment project [1] - Zhuhai Hengqin Chip Storage Co., Ltd. will receive 30 million yuan, and Hefei Chip Storage Co., Ltd. and Xi'an Chip Storage Co., Ltd. will receive 50 million yuan and 30 million yuan respectively for the DRAM project [1] Group 2: Profit Forecasts and Turnarounds - Yiling Pharmaceutical expects a net profit of 1.2 billion to 1.3 billion yuan in 2025, recovering from a loss of 725 million yuan in the previous year [2] - Liard anticipates a net profit of 300 million to 380 million yuan in 2025, compared to a loss of 889 million yuan last year, driven by a new strategic cycle focusing on AI [2] - Daming City forecasts a net profit of 140 million to 165 million yuan in 2025, recovering from a loss in the previous year, aided by reduced asset impairment losses [3] - Guanghua Technology expects a net profit of 85 million to 120 million yuan in 2025, recovering from a loss of 205 million yuan last year, due to expansion in specialized chemicals and PCB sectors [3] - Boteng Co. anticipates a net profit of 80 million to 105 million yuan in 2025, recovering from a loss of 288 million yuan, supported by operational efficiency improvements [4] - Shiyida expects a net profit of 31 million to 46 million yuan in 2025, recovering from a loss of 2.34 million yuan last year, driven by business development and cost control [4] - Guochuang High-tech forecasts a net profit of 16 million to 24 million yuan in 2025, recovering from a loss of 49 million yuan, aided by improved receivables management [5][6] Group 3: Share Buybacks - Hengyi Petrochemical plans to repurchase shares with a total fund of no less than 500 million yuan and no more than 1 billion yuan, with a maximum price of 15 yuan per share [7] - Yunyi Electric plans to repurchase shares with a total fund of no less than 100 million yuan and no more than 150 million yuan, with a maximum price of 17 yuan per share [7] - Xidian Pharmaceutical intends to repurchase shares with a total fund of no less than 25 million yuan and no more than 50 million yuan, with a maximum price of 42 yuan per share [7] Group 4: Performance Highlights - Te Yi Pharmaceutical expects a net profit of 70 million to 90 million yuan in 2025, a growth of 241.55% to 339.13% year-on-year [8] - Xingqi Eye Medicine anticipates a net profit of 662 million to 749 million yuan in 2025, a growth of 95.82% to 121.56% year-on-year [8] - Tianhe Co. forecasts a net profit of 41 million to 60 million yuan in 2025, a growth of 84.35% to 169.78% year-on-year [8] - Ruichuang Micro-Nano expects a net profit of approximately 1.1 billion yuan in 2025, a 93% increase year-on-year [9] - Zhongyuan Co. anticipates a net profit of 139 million to 158 million yuan in 2025, a growth of 80% to 105% year-on-year [9] Group 5: Important Corporate Developments - Aolaide has received acceptance for its application to issue securities on the Science and Technology Innovation Board [14] - *ST Songfa's subsidiary signed contracts for the construction of two VLCC super-large oil tankers, expected to positively impact future performance [15] - Chongda Technology's subsidiary signed an investment agreement for a 1 billion yuan IC packaging project in Jiangsu Province [15] - Yinglian Co. signed a strategic agreement with LG Chem to establish a joint laboratory for innovative materials in lithium battery applications [16]

Group 1 - ShenNan Electric A expects a net profit increase of 584.66%-721.59% year-on-year for 2025 [1] - Te Yi Pharmaceutical anticipates a net profit increase of 241.55%-339.13% year-on-year for 2025 [1] - RunTu Co. forecasts a net profit increase of 181.05%-227.89% year-on-year for 2025 [1] - QingSong Co. projects a net profit increase of 137.73%-201.74% year-on-year for 2025 [1] - RuiSheng Intelligent expects a net profit increase of 112.00%-139.99% year-on-year for 2025 [1] - JianKai Technology anticipates a net profit increase of 101.09%-121.20% year-on-year for 2025 [1] - XingQi Eye Medicine forecasts a net profit increase of 95.82%-121.56% year-on-year for 2025 [1] - RuiChuang MicroNano expects a net profit increase of approximately 93% year-on-year for 2025 [1] - TianHe Co. projects a net profit increase of 84.35%-169.78% year-on-year for 2025 [1] - ZhongYuan Co. anticipates a net profit increase of 80%-105% year-on-year for 2025 [1] - YiDao Information expects a net profit increase of 76.04%-128.85% year-on-year for 2025 [1] - ShengDa Bio forecasts a net profit increase of 69.93%-120.90% year-on-year for 2025 [1] - HuaRui Precision anticipates a net profit increase of 68.29%-86.99% year-on-year for 2025 [1] - FangZheng Technology expects a net profit increase of 67.06%-98.14% year-on-year for 2025 [1] - JinLing Hotel projects a net profit increase of 65.37%-90.93% year-on-year for 2025 [1] - QiangYi Co. anticipates a net profit increase of 57.87%-71.17% year-on-year for 2025 [1] - LangBo Technology expects a net profit increase of 57.58%-66.53% year-on-year for 2025 [1] - HuaFeng Measurement and Control forecasts a net profit increase of 46%-78% year-on-year for 2025 [1] - Zhaoyi Innovation anticipates a net profit increase of approximately 46% year-on-year for 2025 [1] - JieChang Drive expects a net profit increase of 40%-55% year-on-year for 2025 [1] - ShengYuan Environmental Protection projects a net profit increase of 31.79%-59.24% year-on-year for 2025 [1] - GuangHa Communication anticipates a net profit increase of 21.83%-31.31% year-on-year for 2025 [1] - MaiHe Co. expects a net profit increase of 19.58%-54.76% year-on-year for 2025 [1] Group 2 - YiLing Pharmaceutical expects a net profit of 1.2 billion to 1.3 billion yuan for 2025, turning profitable year-on-year [1] - LiYade anticipates a net profit of 300 million to 380 million yuan for 2025, turning profitable year-on-year [1] - SiRuiPu expects a net profit of 165 million to 184 million yuan for 2025, turning profitable year-on-year [1] - DaMing City anticipates a net profit of 140 million to 165 million yuan for 2025, turning profitable year-on-year [1] - DaHeng Technology expects a net profit of 106 million yuan for 2025, turning profitable year-on-year [1] - GuangHua Technology projects a net profit of 85 million to 120 million yuan for 2025, turning profitable year-on-year [1] - BoTeng Co. expects a net profit of 80 million to 105 million yuan for 2025, turning profitable year-on-year [2] - ZhongBing HongJian anticipates a net profit of 34 million to 46 million yuan for 2025, turning profitable year-on-year [2]

Core Viewpoint - Boteng Co., Ltd. (300363) forecasts a revenue of 3.35 billion to 3.5 billion yuan for 2025, representing a year-on-year growth of 11% to 16%, and expects a net profit attributable to shareholders of 80 million to 105 million yuan, marking a turnaround from loss to profit [1] Group 1 - The company anticipates steady growth in operating revenue, leading to the gradual realization of business scale effects [1] - Boteng Co., Ltd. is committed to cost reduction and efficiency enhancement, which has resulted in improved operational efficiency and an increase in overall gross margin compared to the previous year [1] - The company has maintained a stable decline in overall expenses, contributing to better financial performance [1] Group 2 - As the company's business recovers, the efficiency of asset utilization is gradually improving [1] - Based on preliminary impairment tests, the company expects a significant reduction in asset impairment losses compared to the previous year [1]

（文章来源：证券日报） 本报讯 1月22日晚间，重庆博腾制药科技股份有限公司（以下简称"博腾股份"）发布2025年度业绩预 告，预计归属于上市公司股东的净利润为8000万元至10500万元，同比扭亏为盈。 2025年度，公司坚定围绕"收入恢复增长，逐步实现扭亏为盈"的经营目标，持续加强业务拓展，提升经 营大盘系统管理水平。公告显示，报告期内，公司预计实现营业收入33.5亿元至35亿元，同比增长11% 至16%，收入增长主要由临床三期至商业化阶段的项目需求驱动。盈利增长主要得益于营业收入增长带 来的规模效应、降本增效和精益运营提升毛利率、费用稳中有降等。此外，随着公司业务恢复增长，公 司资产的使用效率逐步提升，基于初步减值测试，公司本期资产减值损失预计将同比大幅减少。 ...